Current understanding of the interplay between extracellular matrix remodelling and gut permeability in health and disease.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
18
01
2024
accepted:
07
05
2024
revised:
25
03
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
epublish
Résumé
The intestinal wall represents an interactive network regulated by the intestinal epithelium, extracellular matrix (ECM) and mesenchymal compartment. Under healthy physiological conditions, the epithelium undergoes constant renewal and forms an integral and selective barrier. Following damage, the healthy epithelium is restored via a series of signalling pathways that result in remodelling of the scaffolding tissue through finely-regulated proteolysis of the ECM by proteases such as matrix metalloproteinases (MMPs). However, chronic inflammation of the gastrointestinal tract, as occurs in Inflammatory Bowel Disease (IBD), is associated with prolonged disruption of the epithelial barrier and persistent damage to the intestinal mucosa. Increased barrier permeability exhibits distinctive signatures of inflammatory, immunological and ECM components, accompanied by increased ECM proteolytic activity. This narrative review aims to bring together the current knowledge of the interplay between gut barrier, immune and ECM features in health and disease, discussing the role of barrier permeability as a discriminant between homoeostasis and IBD.
Identifiants
pubmed: 38802341
doi: 10.1038/s41420-024-02015-1
pii: 10.1038/s41420-024-02015-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
258Subventions
Organisme : Wellcome Trust (Wellcome)
ID : 210911/Z/18/Z
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/T00746X/1
Informations de copyright
© 2024. The Author(s).
Références
Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11:821–34.
pubmed: 28650209
pmcid: 6104804
doi: 10.1080/17474124.2017.1343143
Meran L, Baulies A, Li VS. Intestinal stem cell niche: the extracellular matrix and cellular components. Stem Cells Int. 2017;2017:7970385.
pubmed: 28835755
pmcid: 5556610
doi: 10.1155/2017/7970385
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786–801.
pubmed: 25415508
pmcid: 4316204
doi: 10.1038/nrm3904
Sengupta N, MacDonald T. The role of matrix metalloproteinases in stromal/epithelial interactions in the gut. Physiology. 2007;22:401–9.
pubmed: 18073413
doi: 10.1152/physiol.00027.2007
Lee SE, Massie I, Meran L, Li VS. Extracellular matrix remodeling in intestinal homeostasis and disease. In: Advances in stem cells and their niches. Elsevier; 2018. Vol. 2, p. 99–140.
Motta JP, Rolland C, Edir A, Florence AC, Sagnat D, Bonnart C, et al. Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation. Mucosal Immunol. 2021;14:667–78.
pubmed: 33674762
pmcid: 8075934
doi: 10.1038/s41385-021-00375-w
Schmidt J, Weigert M, Leuschner C, Hartmann H, Raddatz D, Haak R, et al. Active matrix metalloproteinase‐8 and periodontal bacteria—interlink between periodontitis and inflammatory bowel disease? J Periodontol. 2018;89:699–707.
pubmed: 29574823
doi: 10.1002/JPER.17-0486
Dobre M, Milanesi E, Mănuc TE, Arsene DE, Ţieranu CG, Maj C, et al. Differential intestinal mucosa transcriptomic biomarkers for Crohn’s disease and ulcerative colitis. J Immunol Res. 2018;2018:9208274.
pubmed: 30417021
pmcid: 6207860
doi: 10.1155/2018/9208274
Collins JT, Nguyen A, Badireddy M. Anatomy, abdomen and pelvis, small intestine. StatPearls Publishing; 2017.
Onfroy-Roy L, Hamel D, Foncy J, Malaquin L, Ferrand A. Extracellular matrix mechanical properties and regulation of the intestinal stem cells: when mechanics control fate. Cells. 2020;9:2629.
pubmed: 33297478
pmcid: 7762382
doi: 10.3390/cells9122629
Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14:9–21.
pubmed: 27848962
doi: 10.1038/nrgastro.2016.169
Van Spaendonk H, Ceuleers H, Witters L, Patteet E, Joossens J, Augustyns K, et al. Regulation of intestinal permeability: the role of proteases. World J Gastroenterol. 2017;23:2106.
pubmed: 28405139
pmcid: 5374123
doi: 10.3748/wjg.v23.i12.2106
Mortensen JH, Manon-Jensen T, Jensen MD, Hägglund P, Klinge LG, Kjeldsen J, et al. Ulcerative colitis, Crohn’s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn’s disease. PLoS ONE. 2017;12:e0185855.
pubmed: 29028807
pmcid: 5640222
doi: 10.1371/journal.pone.0185855
Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117–29.
pubmed: 16831596
doi: 10.1053/j.gastro.2006.04.020
Creff J, Malaquin L, Besson A. In vitro models of intestinal epithelium: toward bioengineered systems. J Tissue Eng. 2021;12:2041731420985202.
pubmed: 34104387
pmcid: 8164551
doi: 10.1177/2041731420985202
Umar S. Intestinal stem cells. Curr Gastroenterol Rep. 2010;12:340–8.
pubmed: 20683682
pmcid: 2965634
doi: 10.1007/s11894-010-0130-3
Pender SL, MacDonald TT. Matrix metalloproteinases and the gut—new roles for old enzymes. Curr Opin Pharm. 2004;4:546–50.
doi: 10.1016/j.coph.2004.06.005
Fonseca-Camarillo G, Yamamoto-Furusho JK. Immunoregulatory pathways involved in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:2188–93.
pubmed: 26111210
doi: 10.1097/MIB.0000000000000477
Derkacz A, Olczyk P, Jura-Półtorak A, Olczyk K, Komosinska-Vassev K. The diagnostic usefulness of circulating profile of extracellular matrix components: sulfated glycosaminoglycans (SGAG), hyaluronan (HA) and extracellular part of syndecan-1 (SCD138) in patients with Crohn’s disease and ulcerative colitis. J Clin Med. 2021;10:1722.
pubmed: 33923501
pmcid: 8073401
doi: 10.3390/jcm10081722
Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123:4195–200.
pubmed: 21123617
pmcid: 2995612
doi: 10.1242/jcs.023820
Hu M, Ling Z, Ren X. Extracellular matrix dynamics: tracking in biological systems and their implications. J Biol Eng. 2022;16:1–13.
doi: 10.1186/s13036-022-00292-x
Bos S, Laukens D. Metabolic modulation during intestinal fibrosis. J Dig Dis. 2020;21:319–25.
pubmed: 32406133
doi: 10.1111/1751-2980.12882
Raeeszadeh-Sarmazdeh M, Do LD, Hritz BG. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells. 2020;9:1313.
pubmed: 32466129
pmcid: 7290391
doi: 10.3390/cells9051313
Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1–73.
pubmed: 28413025
pmcid: 5430303
doi: 10.1016/bs.pmbts.2017.02.005
Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta Mol Cell Res. 2010;1803:39–54.
doi: 10.1016/j.bbamcr.2009.09.015
Almalki SG, Agrawal DK. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. Stem Cell Res Ther. 2016;7:12.
doi: 10.1186/s13287-016-0393-1
Liu J, Khalil RA. Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Prog Mol Biol Transl Sci. 2017;148:355–420.
pubmed: 28662828
pmcid: 5548434
doi: 10.1016/bs.pmbts.2017.04.003
Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA. 1990;87:5578–82.
pubmed: 2164689
pmcid: 54368
doi: 10.1073/pnas.87.14.5578
Monteleone I, Federici M, Sarra M, Franzè E, Casagrande V, Zorzi F, et al. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology. 2012;143:1277–87.
pubmed: 22819866
doi: 10.1053/j.gastro.2012.07.016
Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17:38–53.
pubmed: 27932800
doi: 10.1038/nrc.2016.115
Breynaert C, de Bruyn M, Arijs I, Cremer J, Martens E, Van Lommel L, et al. Genetic deletion of tissue inhibitor of metalloproteinase-1/TIMP-1 alters inflammation and attenuates fibrosis in dextran sodium sulphate-induced murine models of colitis. J Crohns Colitis. 2016;10:1336–50.
pubmed: 27194531
doi: 10.1093/ecco-jcc/jjw101
Bein A, Lubetzky R, Mandel D, Schwartz B. TIMP-1 inhibition of occludin degradation in Caco-2 intestinal cells: a potential protective role in necrotizing enterocolitis. Pediatr Res. 2015;77:649–55.
pubmed: 25665057
doi: 10.1038/pr.2015.26
Dean RA, Butler GS, Hamma-Kourbali Y, Delbé J, Brigstock DR, Courty J, et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol. 2007;27:8454–65.
pubmed: 17908800
pmcid: 2169415
doi: 10.1128/MCB.00821-07
Thomson CA, Nibbs RJ, McCoy KD, Mowat AM. Immunological roles of intestinal mesenchymal cells. Immunology. 2020;160:313–24.
pubmed: 32181492
pmcid: 7370112
doi: 10.1111/imm.13191
Chalkidi N, Paraskeva C, Koliaraki V. Fibroblasts in intestinal homeostasis, damage, and repair. Front Immunol. 2022;13:924866.
pubmed: 36032088
pmcid: 9399414
doi: 10.3389/fimmu.2022.924866
Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4:33–46.
pubmed: 28560287
pmcid: 5439240
doi: 10.1016/j.jcmgh.2017.03.007
Hageman JH, Heinz MC, Kretzschmar K, van der Vaart J, Clevers H, Snippert HJ. Intestinal regeneration: regulation by the microenvironment. Dev Cell. 2020;54:435–46.
pubmed: 32841594
doi: 10.1016/j.devcel.2020.07.009
Sommer K, Wiendl M, Müller TM, Heidbreder K, Voskens C, Neurath MF, et al. Intestinal mucosal wound healing and barrier integrity in IBD–crosstalk and trafficking of cellular players. Front Med. 2021;8:643973.
doi: 10.3389/fmed.2021.643973
Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 2018;175:372–386.e17.
pubmed: 30270042
pmcid: 6176871
doi: 10.1016/j.cell.2018.08.067
Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178:714–730.e22.
pubmed: 31348891
pmcid: 6662628
doi: 10.1016/j.cell.2019.06.029
Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744–52.
pubmed: 23878165
doi: 10.1136/gutjnl-2012-304066
Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology. 2000;119:1740–4.
pubmed: 11113095
doi: 10.1053/gast.2000.20231
Xiong Y, Xu G, Chen M, Ma H. Intestinal uptake and tolerance to food antigens. Front Immunol. 2022;13:906122.
pubmed: 35757706
pmcid: 9226482
doi: 10.3389/fimmu.2022.906122
Markovic M, Zur M, Garsiani S, Porat D, Cvijić S, Amidon GL, et al. The role of paracellular transport in the intestinal absorption and biopharmaceutical characterization of minoxidil. Pharmaceutics. 2022;14:1360.
pubmed: 35890257
pmcid: 9320695
doi: 10.3390/pharmaceutics14071360
Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol. 2011;73:283–309.
pubmed: 20936941
pmcid: 4655434
doi: 10.1146/annurev-physiol-012110-142150
Monaco A, Ovryn B, Axis J, Amsler K. The epithelial cell leak pathway. Int J Mol Sci. 2021;22:7677.
pubmed: 34299297
pmcid: 8305272
doi: 10.3390/ijms22147677
Zuo L, Kuo WT, Turner JR. Tight junctions as targets and effectors of mucosal immune homeostasis. Cell Mol Gastroenterol Hepatol. 2020;10:327–40.
pubmed: 32304780
pmcid: 7326733
doi: 10.1016/j.jcmgh.2020.04.001
Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009;27:313–38.
pubmed: 19302043
doi: 10.1146/annurev.immunol.021908.132657
Mörbe UM, Jørgensen PB, Fenton TM, von Burg N, Riis LB, Spencer J, et al. Human gut-associated lymphoid tissues (GALT); diversity, structure, and function. Mucosal Immunol. 2021;14:793–802.
pubmed: 33753873
doi: 10.1038/s41385-021-00389-4
Kotredes KP, Thomas B, Gamero AM. The protective role of type I interferons in the gastrointestinal tract. Front Immunol. 2017;8:410.
pubmed: 28428788
pmcid: 5382159
doi: 10.3389/fimmu.2017.00410
Schnoor M, Betanzos A, Weber D, Parkos C. Guanylate-binding protein-1 is expressed at tight junctions of intestinal epithelial cells in response to interferon-γ and regulates barrier function through effects on apoptosis. Mucosal Immunol. 2009;2:33–42.
pubmed: 19079332
doi: 10.1038/mi.2008.62
Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50:992–1006.
pubmed: 30995511
doi: 10.1016/j.immuni.2019.03.017
Scott NA, Mann ER. Regulation of mononuclear phagocyte function by the microbiota at mucosal sites. Immunology. 2020;159:26–38.
pubmed: 31777068
doi: 10.1111/imm.13155
Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298–306.
pubmed: 21677746
doi: 10.1038/nature10208
Tourkochristou E, Triantos C, Mouzaki A. The influence of nutritional factors on immunological outcomes. Front Immunol. 2021;12:665968.
pubmed: 34135894
pmcid: 8201077
doi: 10.3389/fimmu.2021.665968
Catalán D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillón JC, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12:611795.
pubmed: 33995344
pmcid: 8118522
doi: 10.3389/fimmu.2021.611795
Bertolini TB, Biswas M, Terhorst C, Daniell H, Herzog RW, Piñeros AR. Role of orally induced regulatory T cells in immunotherapy and tolerance. Cell Immunol. 2021;359:104251.
pubmed: 33248367
doi: 10.1016/j.cellimm.2020.104251
Bein A, Shin W, Jalili-Firoozinezhad S, Park MH, Sontheimer-Phelps A, Tovaglieri A, et al. Microfluidic organ-on-a-chip models of human intestine. Cell Mol Gastroenterol Hepatol. 2018;5:659–68.
pubmed: 29713674
pmcid: 5924739
doi: 10.1016/j.jcmgh.2017.12.010
Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol. 2014;20:64.
pubmed: 24415859
pmcid: 3886034
doi: 10.3748/wjg.v20.i1.64
Stephens M, von der Weid PY. Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner. Gut Microbes. 2020;11:421–32.
pubmed: 31203717
doi: 10.1080/19490976.2019.1629235
Furman D, Chang J, Lartigue L, Bolen CR, Haddad F, Gaudilliere B, et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med. 2017;23:174–84.
pubmed: 28092664
pmcid: 5320935
doi: 10.1038/nm.4267
Fingleton B. Matrix metalloproteinases as regulators of inflammatory processes. Biochim Biophys Acta Mol Cell Res. 2017;1864:2036–42.
pubmed: 28502592
doi: 10.1016/j.bbamcr.2017.05.010
Onali S, Favale A, Fantini MC. The resolution of intestinal inflammation: the peace-keeper’s perspective. Cells. 2019;8:344.
pubmed: 30979024
pmcid: 6523641
doi: 10.3390/cells8040344
Coskun M, Olsen J, Seidelin JB, Nielsen OH. MAP kinases in inflammatory bowel disease. Clin Chim Acta. 2011;412:513–20.
pubmed: 21185271
doi: 10.1016/j.cca.2010.12.020
Gagliani N, Vesely MCA, Iseppon A, Brockmann L, Xu H, Palm NW, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015;523:221–5.
pubmed: 25924064
pmcid: 4498984
doi: 10.1038/nature14452
Watanabe S, Alexander M, Misharin AV, Budinger GS. The role of macrophages in the resolution of inflammation. J Clin Invest. 2019;129:2619–28.
pubmed: 31107246
pmcid: 6597225
doi: 10.1172/JCI124615
Proto JD, Doran AC, Gusarova G, Yurdagul A, Sozen E, Subramanian M, et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity. 2018;49:666–77.
pubmed: 30291029
doi: 10.1016/j.immuni.2018.07.015
De Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
pubmed: 26627550
doi: 10.1038/nrgastro.2015.186
Wei J, Feng J. Signaling pathways associated with inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov. 2010;4:105–17.
pubmed: 20001899
doi: 10.2174/187221310791163071
Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Crohn’s disease and ulcerative colitis show unique cytokine profiles. Cureus. 2017;9:e1177.
pubmed: 28533995
pmcid: 5438231
Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, et al. TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676–86.
pubmed: 24908389
doi: 10.1038/ni.2920
Weber M, Hauschild R, Schwarz J, Moussion C, De Vries I, Legler DF, et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science. 2013;339:328–32.
pubmed: 23329049
doi: 10.1126/science.1228456
Zhu Y, Huang Y, Ji Q, Fu S, Gu J, Tai N, et al. Interplay between extracellular matrix and neutrophils in diseases. J Immunol Res. 2021;2021:1–11.
Padmanabhan J, Gonzalez AL. The effects of extracellular matrix proteins on neutrophil-endothelial interaction―a roadway to multiple therapeutic opportunities. Yale J Biol Med. 2012;85:167.
pubmed: 22737047
pmcid: 3375712
Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiol Rev. 2019;99:1223–48.
pubmed: 30758246
doi: 10.1152/physrev.00012.2018
Islam S, Chuensirikulchai K, Khummuang S, Keratibumrungpong T, Kongtawelert P, Kasinrerk W, et al. Accumulation of versican facilitates wound healing: implication of its initial ADAMTS-cleavage site. Matrix Biol. 2020;87:77–93.
pubmed: 31669737
doi: 10.1016/j.matbio.2019.10.006
Derkacz A, Olczyk P, Olczyk K, Komosinska-Vassev K. The role of extracellular matrix components in inflammatory bowel diseases. J Clin Med. 2021;10:1122.
pubmed: 33800267
pmcid: 7962650
doi: 10.3390/jcm10051122
Valatas V, Filidou E, Drygiannakis I, Kolios G. Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface. Ann Gastroenterol. 2017;30:393.
pubmed: 28655975
pmcid: 5479991
Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022;298:101530.
pubmed: 34953859
doi: 10.1016/j.jbc.2021.101530
Roulis M, Flavell RA. Fibroblasts and myofibroblasts of the intestinal lamina propria in physiology and disease. Differentiation. 2016;92:116–31.
pubmed: 27165847
doi: 10.1016/j.diff.2016.05.002
Bainbridge P. Wound healing and the role of fibroblasts. J Wound Care. 2013;22:407–12.
pubmed: 23924840
doi: 10.12968/jowc.2013.22.8.407
Brügger MD, Valenta T, Fazilaty H, Hausmann G, Basler K. Distinct populations of crypt-associated fibroblasts act as signaling hubs to control colon homeostasis. PLoS Biol. 2020;18:e3001032.
pubmed: 33306673
pmcid: 7758045
doi: 10.1371/journal.pbio.3001032
Tommelein J, Verset L, Boterberg T, Demetter P, Bracke M, De Wever O. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol. 2015;5:63.
pubmed: 25853091
pmcid: 4369728
doi: 10.3389/fonc.2015.00063
Shimshoni E, Yablecovitch D, Baram L, Dotan I, Sagi I. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut. 2015;64:367–72.
pubmed: 25416065
doi: 10.1136/gutjnl-2014-308048
Zhao JF, Ling FM, Li JR, Chen YD, Huang L, Zhu LR. Role of non‐inflammatory factors in intestinal fibrosis. J Dig Dis. 2020;21:315–8.
pubmed: 32406603
doi: 10.1111/1751-2980.12883
Al-Sadi R, Youssef M, Rawat M, Guo S, Dokladny K, Haque M, et al. MMP-9-induced increase in intestinal epithelial tight permeability is mediated by p38 kinase signaling pathway activation of MLCK gene. Am J Physiol Gastrointest Liver Physiol. 2019;316:G278–90.
pubmed: 30543452
doi: 10.1152/ajpgi.00126.2018
Marônek M, Marafini I, Gardlík R, Link R, Troncone E, Monteleone G. Metalloproteinases in inflammatory bowel diseases. J Inflamm Res. 2021;14:1029.
pubmed: 33790618
pmcid: 8001665
doi: 10.2147/JIR.S288280
Komosinska-Vassev K, Kałużna A, Jura-Półtorak A, Derkacz A, Olczyk K. Circulating profile of ECM-related proteins as diagnostic markers in inflammatory bowel diseases. J Clin Med. 2022;11:5618.
pubmed: 36233486
pmcid: 9570505
doi: 10.3390/jcm11195618
Sampaio Moura N, Schledwitz A, Alizadeh M, Patil SA, Raufman JP. Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer. Front Oncol. 2024;13:1325095.
pubmed: 38288108
pmcid: 10824561
doi: 10.3389/fonc.2023.1325095
Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17:1147–55.
pubmed: 29735645
pmcid: 5984693
doi: 10.1158/1535-7163.MCT-17-0646
Al-Sadi R, Engers J, Haque M, King S, Al-Omari D, Ma TY. Matrix metalloproteinase-9 (MMP-9) induced disruption of intestinal epithelial tight junction barrier is mediated by NF-κB activation. PLoS ONE. 2021;16:e0249544.
pubmed: 33826658
pmcid: 8026081
doi: 10.1371/journal.pone.0249544
Lindholm M, Manon-Jensen T, Madsen GI, Krag A, Karsdal MA, Kjeldsen J, et al. Extracellular matrix fragments of the basement membrane and the interstitial matrix are serological markers of intestinal tissue remodeling and disease activity in dextran sulfate sodium colitis. Dig Dis Sci. 2019;64:3134–42.
pubmed: 31123972
doi: 10.1007/s10620-019-05676-6
Xu X, Jackson PL, Tanner S, Hardison MT, Abdul Roda M, Blalock JE, et al. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS ONE. 2011;6:e15781.
pubmed: 21249198
pmcid: 3020950
doi: 10.1371/journal.pone.0015781
Lin J, Wu J, Wang F, Tang F, Sun J, Xu B, et al. QingBai decoction regulates intestinal permeability of dextran sulphate sodium‐induced colitis through the modulation of notch and NF‐κB signalling. Cell Prolif. 2019;52:e12547.
pubmed: 30657238
pmcid: 6496276
doi: 10.1111/cpr.12547
Opdenakker G, Vermeire S, Abu El-Asrar A. How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities? Front Immunol. 2022;13:983964.
de Bruyn M, Arijs I, De Hertogh G, Ferrante M, Van Assche G, Rutgeerts P, et al. Serum neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn’s disease. J. Crohns Colitis. 2015;9:1079–87.
pubmed: 26351381
doi: 10.1093/ecco-jcc/jjv148
de Bruyn M, Arijs I, Wollants WJ, Machiels K, Van Steen K, Van Assche G, et al. Neutrophil gelatinase B–associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20:1198–207.
pubmed: 24871805
doi: 10.1097/MIB.0000000000000068
Kubben FJGM, Sier CFM, Hawinkels LJAC, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43:1869–76.
pubmed: 17604154
doi: 10.1016/j.ejca.2007.05.013
Di Carlo A. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase‑9 (MMP‑9) and their complex MMP‑9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett. 2013;5:1677–81.
pubmed: 23760084
doi: 10.3892/ol.2013.1252
Bai X, Bai G, Tang L, Liu L, Li Y, Jiang W. Changes in MMP‑2, MMP‑9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis. Exp Ther Med. 2020;20:269–74.
pubmed: 32536995
pmcid: 7282134
doi: 10.3892/etm.2020.8710
Garg P, Ravi A, Patel NR, Roman J, Gewirtz AT, Merlin D, et al. Matrix metalloproteinase-9 regulates MUC-2 expression through its effect on goblet cell differentiation. Gastroenterology. 2007;132:1877–89.
pubmed: 17484881
doi: 10.1053/j.gastro.2007.02.048
Xiao Y, Lian H, Zhong XS, Krishnachaitanya SS, Cong Y, Dashwood RH, et al. Matrix metalloproteinase 7 contributes to intestinal barrier dysfunction by degrading tight junction protein Claudin-7. Front Immunol. 2022;13:1020902.
pubmed: 36275703
pmcid: 9581388
doi: 10.3389/fimmu.2022.1020902
Nighot M, Ganapathy AS, Saha K, Suchanec E, Castillo EF, Gregory A, et al. Matrix metalloproteinase MMP-12 promotes macrophage transmigration across intestinal epithelial tight junctions and increases severity of experimental colitis. J Crohns Colitis. 2021;15:1751–65.
pubmed: 33836047
pmcid: 8495490
doi: 10.1093/ecco-jcc/jjab064
Vizoso FJ, González LO, Corte MD, Corte MG, Bongera M, Martínez A, et al. Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2006;41:1050–5.
pubmed: 16938718
doi: 10.1080/00365520600554667
Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, Lodens S, De Rycke R, Van Wonterghem E, et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med. 2013;5:932–48.
pmcid: 3721470
doi: 10.1002/emmm.201202100
Curciarello R, Sobande T, Jones S, Giuffrida P, Di Sabatino A, Docena GH, et al. Human neutrophil elastase proteolytic activity in ulcerative colitis favors the loss of function of therapeutic monoclonal antibodies. J Inflamm Res. 2020;13:233–43.
pubmed: 32547155
pmcid: 7251227
doi: 10.2147/JIR.S234710
Motta J, Magne L, Descamps D, Rolland C, Squarzoni–Dale C, Rousset P, et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology. 2011;140:1272–82.
pubmed: 21199654
doi: 10.1053/j.gastro.2010.12.050
Solà-Tapias N, Vergnolle N, Denadai-Souza A, Barreau F. The interplay between genetic risk factors and proteolytic dysregulation in the pathophysiology of inflammatory bowel disease. J Crohns Colitis. 2020;14:1149–61.
pubmed: 32090263
doi: 10.1093/ecco-jcc/jjaa033
Jacenik D, Fichna J, Małecka-Wojciesko E, Mokrowiecka A. Protease-activated receptors – key regulators of inflammatory bowel diseases progression. J Inflamm Res. 2021;14:7487–97.
pubmed: 35002281
pmcid: 8721023
doi: 10.2147/JIR.S335502
Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161:1903–15.
pubmed: 12414536
pmcid: 1850779
doi: 10.1016/S0002-9440(10)64466-5
Chin AC, Vergnolle N, MacNaughton WK, Wallace JL, Hollenberg MD, Buret AG. Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci. 2003;100:11104–9.
pubmed: 12960392
pmcid: 196934
doi: 10.1073/pnas.1831452100
Pruteanu M, Hyland NP, Clarke DJ, Kiely B, Shanahan F. Degradation of the extracellular matrix components by bacterial-derived metalloproteases: implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1189–200.
pubmed: 20853433
doi: 10.1002/ibd.21475
Yablecovitch D, Kopylov U, Lahat A, Amitai MM, Klang E, Ben-Ami Shor D, et al. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis. Ther Adv Gastroenterol. 2019;12:1756284819881590.
doi: 10.1177/1756284819881590
Leeman MF, McKay JA, Murray GI. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol. 2002;55:758–62.
pubmed: 12354802
pmcid: 1769766
doi: 10.1136/jcp.55.10.758
Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer. 2003;107:541–50.
pubmed: 14520690
doi: 10.1002/ijc.11436
Hilska M, Roberts PJ, Collan YU, Laine VJO, Kössi J, Hirsimäki P, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–23.
pubmed: 17455256
doi: 10.1002/ijc.22747
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005–14.
pubmed: 26412349
pmcid: 4701034
doi: 10.1056/NEJMoa1510764
Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, et al. Serum biomarkers for inflammatory bowel disease. Front Med. 2020;7:123.
doi: 10.3389/fmed.2020.00123
de Bruyn M, Breynaert C, Arijs I, De Hertogh G, Geboes K, Thijs G, et al. Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease. Nat Commun. 2017;8:15384.
pubmed: 28561062
pmcid: 5460016
doi: 10.1038/ncomms15384
Kapsoritakis AN, Kapsoritaki AI, Davidi IP, Lotis VD, Manolakis AC, Mylonis PI, et al. Imbalance of tissue inhibitors of metalloproteinases (TIMP)–1 and–4 serum levels, in patients with inflammatory bowel disease. BMC Gastroenterol. 2008;8:8.
doi: 10.1186/1471-230X-8-55
Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother. 2012;35:502–12.
pubmed: 22735808
pmcid: 3402087
doi: 10.1097/CJI.0b013e3182619c8e
Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer—trials and tribulations. Science. 2002;295:2387–92.
pubmed: 11923519
doi: 10.1126/science.1067100
Macaulay VM, O’Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 1999;5:513–20.
pubmed: 10100701
King J, Zhao J, Clingan P, Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res. 2003;23:639–45.
pubmed: 12680160
Fields GB. The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma. Cells. 2019;8:984.
pubmed: 31461880
pmcid: 6769477
doi: 10.3390/cells8090984
Darling NJ, Mobbs CL, González-Hau AL, Freer M, Przyborski S. Bioengineering novel in vitro co-culture models that represent the human intestinal mucosa with improved Caco-2 structure and barrier function. Front Bioeng Biotechnol. 2020;8:992.
pubmed: 32984279
pmcid: 7487342
doi: 10.3389/fbioe.2020.00992
Sarah Cripps. Inflammatory bowel disease: symptoms an ddiagnosis. Pharm J. 2021. https://pharmaceutical-journal.com/article/ld/inflammatory-bowel-disease-symptoms-and-diagnosis .
Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin. 2019;99:1051–62.
Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-) evolutionary perspective. Nat Rev Immunol. 2009;9:883–9.
pubmed: 19935807
doi: 10.1038/nri2660
Tapias NS. The involvement of the three main inflammatory bowel disease pathways and the secretion of trypsin proteolytic activity on intestinal epithelial cells. 2018.
Montgomery RK, Carlone DL, Richmond CA, Farilla L, Kranendonk MEG, Henderson DE, et al. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. Proc Natl Acad Sci USA. 2011;108:179–84.
pubmed: 21173232
doi: 10.1073/pnas.1013004108
Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, et al. The Pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 2012;149:146–58.
pubmed: 22464327
pmcid: 3563328
doi: 10.1016/j.cell.2012.02.042
Aldred EM. Pharmacology: a handbook for complementary healthcare professionals. Elsevier Health Sciences; 2008.
Jaladanki RN, Wang JY. Regulation of gastrointestinal mucosal growth. Biota Publishing; 2016.
Bhat AA, Uppada S, Achkar IW, Hashem S, Yadav SK, Shanmugakonar M, et al. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk. Front Physiol. 2019;9:1942.
pubmed: 30728783
pmcid: 6351700
doi: 10.3389/fphys.2018.01942
Musa MA, Kabir M, Hossain MI, Ahmed E, Siddique A, Rashid H, et al. Measurement of intestinal permeability using lactulose and mannitol with conventional five hours and shortened two hours urine collection by two different methods: HPAE-PAD and LC-MSMS. PLoS ONE. 2019;14:e0220397.
pubmed: 31393913
pmcid: 6687120
doi: 10.1371/journal.pone.0220397